| Date | Title | Description |
| 29.06.2026 | Ascent-led consortium strikes second deal in healthcare space | Credit: 123RF.com
A consortium led by private equity firm Ascent Capital is investing in a healthcare solutions company, roughly nine months after investing in a Kerala-based hospital chain.
The mid-market PE firm, along with co-investor Vi... |
| 21.11.2024 | Bain Capital-backed 360 ONE Asset bets on CDMO player from TPG’s portfolio | Tarun Sharma, head of healthcare and consumer, 360 One Asset
360 ONE Asset, an asset management firm backed by private equity firm Bain Capital, has invested in TPG-backed contract drugmaker OneSource Specialty Pharma in a secondary transac... |
| 11.09.2024 | Strides Pharma secures approval for OneSource CDMO creation | Strides Pharma Science Limited announced today that it has received approval from equity shareholders and secured creditors to create OneSource, India’s first specialty pharma Contract Development and Manufacturing Organization (CDMO).
The ... |
| 06.09.2024 | Strides Pharma secures USFDA nod for asthma drug, gains exclusivity | Strides Pharma Science Limited announced today that its subsidiary has received U.S. Food and Drug Administration (FDA) approval for generic Theophylline Extended-Release Tablets in 300 mg and 450 mg strengths. The company has been granted ... |
| 29.05.2024 | Health secy highlights India's achievements, future goals at WHO assembly | - |
| 22.05.2024 | Strides rallies 9% intraday, hits over 3 year high on healthy Q4 results | - |
| 22.05.2024 | Strides Pharma Q4 results: Net profit declines 24% to Rs 10.44 crore | - |
| 22.05.2024 | Strides Pharma Q4 Results: Posts net profit of Rs 10.44 cr, revenue up 5.6% | - |
| 21.05.2024 | Expect formulations biz to outpace API biz: Biocon Group CEO Peter Bains | - |
| 08.05.2024 | Dr Reddy's Labs slumps 5% as brokerages give 'Reduce' call post Q4 earnings | - |
| 04.05.2024 | Productivity loss due to oral cancer in India in 2022 at $5.6 bn: Study | - |
| 02.05.2024 | India, New Zealand look to boost collaboration in pharma, digital trade | - |
| 01.05.2024 | Mizoram sees alarming surge in TB deaths, 108 succumb to disease in 2023 | - |
| 05.03.2024 | Strides Pharma receives USFDA approval for neurology medication Gabapentin | Strides Pharma Science Limited (Strides) has received approval of Gabapentin Tablets USP, in strengths of 600 mg and 800 mg, by the United States Food & Drug Administration (USFDA). This announcement is a step towards expanding Strides'... |
| 01.11.2021 | With the help of the NY governor's office, Strides Pharma acquires new manufacturing site | For a long time, migraine sufferers were stuck with the same old medicines and advice. Try some triptans, change your diet, maybe even see if a narcotic might help — but no major drug advances to prevent or stop debilitating migraine episod... |
| 01.11.2021 | Perceptive steers LianBio's globally connected China strategy to $325M IPO | LianBio was founded to tackle a big mission: to take the in-licensing strategy that’s been popularized in China over the past decade and supercharge it with rich global connections and a creative approach to dealmaking.... |
| 01.11.2021 | With the help of the NY governor's office, Strides Pharma acquires new manufacturing site | An Indian biopharma has seen its US business increase accordingly as it’s expanded its portfolio, and the company is acquiring a manufacturing site on the New York/New Jersey border to up annual capacity and avoi... |
| 01.11.2021 | Weeks into CEO shakeup, Mirati bids adieu to a pair of C-suiters with KRAS drug filing around the corner | Mirati is on the cusp of emerging as the sole challenger against Amgen in the suddenly hot KRAS inhibitor market and thinks it has the man to take it across the finish line. But new leadership often means shakeups, and now two ... |
| 01.11.2021 | Merck dives even further into cytokine research as deal spree continues | Merck’s new leadership hasn’t been shy about its desire to spend, agreeing to drop $11.5 billion on a new biotech and promising to dole out more as the expiration date on the company’s money machine slowly approaches.
On Mo... |
| 01.11.2021 | In key win, AbbVie lands FDA approval for Allergan's blurred-vision eye drop | AbbVie’s age-related blurry vision drug for aging adults was given the OK by the FDA Friday, making it the first eye drop to treat an eye condition that affects 128 million Americans.
Formerly AGN-190584, the drug has prov... |
| 01.11.2021 | Tal Zaks' post-Moderna future is now in view as he joins biotech VC blue-chipper OrbiMed | It’s hard to imagine what comes next for a physician-scientist who’s developed one of the most lucrative vaccines in biopharma history. On Monday — a month after leaving his post at Moderna — Tal Zaks cleared up some of th... |
| 01.11.2021 | With the help of the NY governor's office, Strides Pharma acquires new manufacturing site | Merck’s $11.5 billion Acceleron Pharma buyout may not happen quite as soon as the Kenilworth, NJ-based pharma company had hoped.
On Friday, Merck revealed that it had temporarily withdrawn its premerger notification and report form — which ... |
| 01.11.2021 | With the help of the NY governor's office, Strides Pharma acquires new manufacturing site | The 2016 meeting of the Oligonucleotide Therapeutics Society in Montreal began with a rare mix of promise and elation.
That year, the 27-year-old biotech Ionis showed that a drug, later branded Spinraza, could dramatically alter the course ... |
| 19.03.2021 | Strides Pharma arm raises $195 million through series B, C funding | Bengaluru-based Stelis Biopharma, the biotech arm of Strides Pharma Science, has raised $195 million through Series B and Series C funding, which the company will use to repay debt and for general corporate purposes.
Following the funding, ... |
| 19.03.2021 | Bangalore based company Stelis Biopharma secures US $ 195 million in Series B and C combined | Stelis Biopharma, the biotech arm of Strides Pharma Science, announced on 19th March 2021 that it has raised US $ 195 million in its Series B and Series C rounds combined. The Series C round was led by TPG Growth along with participation fr... |
| 17.07.2019 | FDA warns Strides Pharma for uncontrolled document shredding | The FDA warned Indian generic drugmaker Strides Pharma earlier this month over good manufacturing practice (GMP) violations at its Puducherry facility that included uncontrolled shredding of documents and inade... |
